The potential for synergistic combination treatment with the spliceosome inhibitor E7107 and the MDM2–p53 antagonist RG7388 was investigated in leukaemia–lymphoma cell lines and primary CLL samples. This evidence concerns the gene MDM2 and B-cell chronic lymphocytic leukemia.